Mexico Cuba Dominican Republic Puerto Rico Panama Colombia Venezuela Ecuador Peru Bolivia Brazil Paraguay Uruguay Chile Argentina
🌎 NEW: Raíces, your Latin American bloodline, just €15 Pick your country and we model your DNA against its indigenous peoples plus every Old-World source of Latin history, on an interactive map.
Discover Raíces
United States Canada
🦅 NEW: El Gringo, your North American bloodline (USA & Canada), just €15 Your Native American, British, French, German, Scandinavian & African American roots, modelled on an interactive map.
Discover El Gringo
✡️
✡️ NEW: Am Yisrael, your Jewish Diaspora report, just €15 Ancient Israelite & Levantine core + your community's diaspora host admixture — Ashkenazi, Sephardi, Mizrahi & more, on a Jerusalem-centred map.
Discover Am Yisrael
🌍
🌍 NEW: Sankofa, your African Diaspora report, just €15 Regional West, Central & East African modelling plus your community's European and Amerindian layers, for African American, Afro-Caribbean, Afro-Brazilian, Afro-Latino and continental African roots.
Discover Sankofa

Study Information

2025
World

Abstract

The chemokine receptor variant CCR5delta32 is linked to HIV-1 resistance and other conditions. Its evolutionary history and allele frequency (10%–16%) in European populations have been extensively debated. We provide a detailed perspective of the evolutionary history of the deletion through time and space. We discovered that the CCR5delta32 allele arose on a pre-existing haplotype consisting of 84 variants. Using this information, we developed a haplotype-aware probabilistic model to screen 934 low-coverage ancient genomes and traced the origin of the CCR5delta32 deletion to at least 6,700 years before the present (BP) in the Western Eurasian Steppe region. Furthermore, we present strong evidence for positive selection acting upon the CCR5delta32 haplotype between 8,000 and 2,000 years BP in Western Eurasia and show that the presence of the haplotype in Latin America can be explained by post-Columbian genetic exchanges. Finally, we point to complex CCR5delta32 genotype-haplotype-phenotype relationships, which demand consideration when targeting the CCR5 receptor for therapeutic strategies.

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. Learn more

🧭 Find your report